S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.46 (+0.59%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.87 (-1.00%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.49%)
GE   110.89 (+0.87%)
DIS   79.90 (-0.19%)
AMC   7.57 (-4.30%)
PFE   32.10 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
NASDAQ:HGEN

Humanigen (HGEN) Stock Forecast, Price & News

$0.0091
0.00 (-8.08%)
(As of 05:37 PM ET)
Compare
Today's Range
$0.0090
$0.01
50-Day Range
$0.01
$0.20
52-Week Range
$0.01
$0.26
Volume
681,124 shs
Average Volume
2.94 million shs
Market Capitalization
$1.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$0.50

HGEN stock logo

About Humanigen (NASDAQ:HGEN) Stock

Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response. The company is developing lenzilumab, an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF), to treat cytokine storm associated with COVID-19 for which it has completed a Phase 3 study and is the focus of a Phase 2/3 study sponsored by the NIH. It is also developing lenzilumab, which is associated with CD19-targeted CAR-T cell therapies, as well as exploring the effectiveness of lenzilumab in other inflammatory conditions, such as acute Graft versus Host Disease in patients undergoing allogeneic hematopoietic stem cell transplantation and in eosinophilic asthma, and rheumatoid arthritis. In addition, the company focuses on studying lenzilumab for patients with chronic myelomonocytic leukemia exhibiting RAS pathway mutations. Its pipeline also includes two other Humaneered monoclonal antibodies, ifabotuzumab, which binds to EphA3, and HGEN005, which targets EMR1, as well as treats a range of eosinophilic diseases, including eosinophilic leukemia as an optimized naked antibody and as the backbone for a novel CAR-T construct. Humanigen, Inc. was incorporated in 2000 and is headquartered in Short Hills, New Jersey.

HGEN Price History

HGEN Stock News Headlines

"This Could be the Biggest Stock Story of 2023"
A.I. is set to create $7 trillion in new wealth but most investors are buying the wrong stocks. Learn what Wall Street insiders are buying here.
Why Is Humanigen (HGEN) Stock Down 72% Today?
A 73-Year-Old Market Signal With 95% Accuracy Just Flashed
This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.
Humanigen Reports Third Quarter 2022 Financial Results
HGEN SHAREHOLDER ALERT: Jakubo - GuruFocus.com
HGEN LAWSUIT ALERT: Levi & Kor - GuruFocus.com
See More Headlines
Receive HGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humanigen and its competitors with MarketBeat's FREE daily newsletter.

HGEN Company Calendar

Last Earnings
11/12/2021
Today
9/27/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HGEN
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$0.50
High Stock Price Forecast
$0.50
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+5,002.0%
Consensus Rating
Reduce
Rating Score (0-4)
1.50
Research Coverage
2 Analysts

Profitability

Net Income
$-70,730,000.00
Net Margins
-3,156.80%
Pretax Margin
-3,156.80%

Debt

Sales & Book Value

Annual Sales
$2.51 million
Book Value
($0.45) per share

Miscellaneous

Free Float
93,240,000
Market Cap
$1.17 million
Optionable
Optionable
Beta
-0.98
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Cameron Durrant M.D. (Age 63)
    MBA, Chairman, CEO & Acting CFO
    Comp: $640k
  • Dr. Dale Chappell M.B.A. (Age 53)
    M.D., MBA, Chief Scientific Officer & Director
    Comp: $410k
  • Mr. Edward P. Jordan M.B.A.Mr. Edward P. Jordan M.B.A. (Age 55)
    Chief Commercial Officer
    Comp: $364.75k
  • Mr. Robert Atwill M.B.A.
    Sr. VP and Head of Asia-Pacific Region & Bus. Devel.













HGEN Stock - Frequently Asked Questions

Should I buy or sell Humanigen stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Humanigen in the last year. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" HGEN shares.
View HGEN analyst ratings
or view top-rated stocks.

What is Humanigen's stock price forecast for 2023?

2 Wall Street research analysts have issued 1 year target prices for Humanigen's shares. Their HGEN share price forecasts range from $0.50 to $0.50. On average, they expect the company's stock price to reach $0.50 in the next twelve months. This suggests a possible upside of 5,002.0% from the stock's current price.
View analysts price targets for HGEN
or view top-rated stocks among Wall Street analysts.

How have HGEN shares performed in 2023?

Humanigen's stock was trading at $0.12 at the start of the year. Since then, HGEN shares have decreased by 91.8% and is now trading at $0.0098.
View the best growth stocks for 2023 here
.

How were Humanigen's earnings last quarter?

Humanigen, Inc. (NASDAQ:HGEN) posted its earnings results on Friday, November, 12th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($0.98) by $0.14. The business had revenue of $1.04 million for the quarter, compared to the consensus estimate of $0.40 million.

When did Humanigen's stock split?

Humanigen's stock reverse split on the morning of Monday, September 14th 2020. The 1-5 reverse split was announced on Friday, September 4th 2020. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 11th 2020. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What is Humanigen's stock symbol?

Humanigen trades on the NASDAQ under the ticker symbol "HGEN."

How do I buy shares of Humanigen?

Shares of HGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Humanigen's stock price today?

One share of HGEN stock can currently be purchased for approximately $0.01.

How much money does Humanigen make?

Humanigen (NASDAQ:HGEN) has a market capitalization of $1.17 million and generates $2.51 million in revenue each year. The company earns $-70,730,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.

How can I contact Humanigen?

Humanigen's mailing address is 533 Airport Boulevard Ste. 400, Burlingame CA, 94010. The official website for the company is www.humanigen.com. The company can be reached via phone at 650-243-3100 or via email at ir@humanigen.com.

This page (NASDAQ:HGEN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -